Tissue remodelling proteases as prognostic factors in colon and rectal cancer by Langenskiöld, Marcus
TISSUE REMODELLING PROTEASES AS 


















Department of Surgery 
Institute of Clinical Sciences at Sahlgrenska Academy 































Paper I was reprinted from Int J Colorectal Dis. 2005 May;20(3):245-52. Increased plasma 
MMP-2 protein expression in lymph node-positive patients with colorectal cancer. 
Langenskiöld M, Holmdahl L, Falk P, Ivarsson ML. Reprinted with permission of 
Springer-Verlag GmbH Heidelberg. 
Paper II was reprinted from J Surg Oncol. 2008 Apr 1;97(5):409-15. Increased TGF-beta 1 
protein expression in patients with advanced colorectal cancer. Langenskiöld M, Holmdahl 
L, Falk P, Angenete E, Ivarsson ML. Reprinted with permission of Wiley-Liss, Inc. a 
subsidiary of John Wiley & Sons, Inc. 
 
 
Printed by Geson Hylte Tryck, Göteborg, Sweden 2009 
© Marcus Langenskiöld, 2009 
http://handle.net/2077/19379 








































Background: Colorectal cancer is the third most common cancer in Sweden and the main 
treatment is surgery. The TNM classification is the principal staging tool, although 
insufficient in identifying all patients with poor survival. The identification of molecular 
prognostic markers would be important in order to further aid in the identification of these 
patients. Components participating in the remodellation of extracellular matrix were 
analysed for their association with tumour progression and survival. 
Methods: Patients with colorectal cancer were included in the studies during 1999-2004. 
Protein expression was evaluated by ELISA technique and immunohistochemistry, and 
related to tumour classifications. The association with cancer specific survival (CSS) was 
analysed by Cox proportional hazard analysis and differences between survival curves 
(Kaplan-Meier method) were evaluated by the Log Rank test.  
Results: The expression of all measured markers were significantly higher in tumour tissue 
compared to tumour free mucosa. Matrix metalloproteinase-1 (MMP-1) protein expression 
in tumour tissue and MMP-2 expression in plasma was associated with increasing tumour 
stage (T-status) and lymph node metastasis in patients without distant metastatic disease. 
When survival data were analysed, MMP-2 in tumour tissue and MMP-1 and -9 expression 
in adjacent tumour free mucosa were associated with CSS in colon cancer. The association 
with CSS was maintained for MMP-1 in multivariate analysis also in patients without 
distant metastatic disease. High levels of urokinase Plasminogen Activator (uPA) 
expression in tumour free mucosa were associated with improved survival, but only in 
patients with rectal cancer. uPA expression below the chosen cut-off value identified M0 
patients with increased risk of poor survival. TGF-beta1 and PAI-1 protein expression was 
associated with metastatic disease and the survival analysis confirmed these results. 
Discussion: Results indicate that the association of systemically measured factors with 
survival is due to their strong correlation with metastatic disease. These findings might 
reflect a generalised response to the metastatic disease. The differential association of 
MMP-1, MMP-9 and uPA expression with cancer specific survival in adjacent tumour free 
mucosa in colon and rectal cancer was unexpected. This also means that prognostic 
information could be available already in the preoperative setting, which could open up the 
opportunity to offer neo-adjuvant therapy to high-risk patients. The results suggest that the 
macroscopically normal mucosa in the tumour-bearing segment reflects local tumour 
progression, and it seems evident that important changes in the microenvironment, even 
remote from the tumour, are present. 
 
Key words: extracellular matrix, survival, staging, colorectal cancer, mucosa, stroma 
 LIST OF PUBLICATIONS 
 
I. Marcus Langenskiöld, Lena Holmdahl, Peter Falk, Marie-Louise Ivarsson. 
Increased MMP-2 protein expression in lymph node positive patients with 
colorectal cancer. Int J Colorectal Dis. 2005 May;20(3):245-52. 
 
II. Marcus Langenskiöld, Lena Holmdahl, Peter Falk, Eva Angenete, Marie-
Louise Ivarsson. Increased TGF-beta1 protein expression in patients with 
advanced colorectal cancer. J Surg Oncol. 2008 Apr 1;97(5):409-15. 
 
III. Marcus Langenskiöld, Lena Holmdahl, Eva Angenete, Peter Falk, Svante 
Nordgren, Marie-Louise Ivarsson. Differential prognostic impact of uPA and 
PAI-1 in colon and rectal cancer. Submitted. 
 
IV. Marcus Langenskiöld, Lena Holmdahl, Eva Angenete, Peter Falk, Christina 
Kåbjörn-Gustafsson, Marie-Louise Ivarsson. Intestinal mucosal MMP-1 is a 
prognostic factor in colon cancer. In manuscript. 
 TABLE OF CONTENTS 
Introduction 1 
Colorectal cancer 1 
Epidemiology 1 
Surgery in colorectal cancer 1 
Survival and Prognosis 2 
Adjuvant treatment 4 
Background 4 
Use of adjuvant treatment for stage II colorectal cancer 4 
Prognostic markers 5 
Molecular prognostic markers 5 
The role of extracellular matrix in tumour biology 7 
Regulatory components of the extracellular matrix 8 
Aims of thesis 10 
Material and methods 11 
Patients 11 
Study patients 11 
Non-study patients during the time period 11 
Paper I 12 
Paper II and IV 12 
Paper III 12 
Tissue sampling & processing 13 
Optimising blood and tissue sampling: the pilot study 13 
Tissue and blood processing 13 
Protein analysis 14 
Statistics 15 
Results & Discussion 17 
Populärvetenskaplig sammanfattning 28 
Ethical aspects 29 
 Acknowledgements 30 
References 33 
Paper I 
Paper II  
Paper III  
Paper IV  
 ABBREVIATIONS 
AJCC  American joint committee on cancer 
APC  Adenomatosis polyposis coli 
BM  Basement membrane 
CEA  Carcinoembryonic antigen 
CIN  Chromosome instability 
CME  Complete mesocolic excision 
CRC  Colorectal cancer 
CSS  Cancer specific survival 
DCC  Deleted in colorectal cancer 
ECM  Extracellular matrix 
EGFR  Epidermal growth factor receptor 
ELISA  Enzyme linked immunosorbent assay 
FLV  Fluorouracil/Leucovorin 
5-FU  5-Fluorouracil 
HR  Hazard ratio 
HRP  Horseradish peroxidase 
Htx-Eo Hematoxylin-Eosin 
LNR  Lymph node ratio 
LV  Leucovorin 
MRI  Magnetic resonance imaging 
MSI  Microsatellite instability 
MSS  Microsatellite stable 
MMP  Matrix metalloproteinase 
mRNA Messenger ribonucleic acid 
PAI-1  Plasminogen Activating Inhibitor-1 
PLSD  Protected least significant difference 
PPS  Plasminogen/plasmin system  
ROC  Receiver operating characteristics 
TGF-β1 Transforming growth factor-β1 
TIL  Tumour infiltrating lymphocyte 
TIMP  Tissue inhibitor of matrix metalloproteinase 
TMB  Tetrametylbenzidine 
TME  Total mesorectal excision 
TNM  Tumour / Node / Metastasis classification  
t-PA  tissue-type Plasminogen Activator 
UICC  International union against cancer (Union international contre le cancer) 
uPA  urokinase Plasminogen Activator 






Colorectal cancer is one of the most common malignant diseases in Sweden, accounting 
for 11% of all malignant cases per year. In 2004, 5670 new cases of colorectal cancer were 
registered (in a population of about 9 million). Colon cancer is more common and accounts 
for 60% of all colorectal cancer cases in males and 68% in females. The average age in 
Sweden at diagnosis is 72 years. The incidence of rectal cancer is approximately 
20/100000 and in colon cancer 40/100000 [1]. Colorectal cancer is, despite improved 
surgery [2] and modern neoadjuvant and adjuvant treatment, still associated with a 
significant mortality rate [3]. In Sweden, the overall 5-year cancer specific survival (CSS) 
for patients with rectal cancer is reported to be 54% for women and 60% for men. Similar 
figures are reported for patients with colon cancer (57% and 59% respectively) [1]. 
Surgery in colorectal cancer  
The main therapy in colorectal cancer is surgery, and adjuvant therapy is added depending 
on the pathological and anatomical diagnosis. In Sweden, rectal cancer patients have been 
offered neo-adjuvant radiotherapy totalling 25 Gy in five fractions [4]. Later reports have 
confirmed the beneficial effect of local radiotherapy regarding local recurrences but not for 
survival [5,6]. No standardised neo-adjuvant therapy is given to colon cancer patients. 
The surgical approach in colon and rectal cancer differs. The operation for colon cancer 
has been the most common intra abdominal operation for malignant disease for general 
surgeons and is characterised by a segmental resection of the tumour and adjacent tumour 
free bowel, mesocolon, artery and vein. The resections performed are right-sided 
hemicolectomy, resection of the transverse colon, left-sided hemicolectomy and resection 
of the sigmoid colon. The procedure for rectal cancer is total mesorectal excision (TME), 
performed as an abdomino-perianal resection or anterior resection depending on the 
tumour position in relation to the anal verge, and is a procedure for specialised colorectal 
surgeons, which has improved results of rectal surgery [2,5]. TME is characterised by the 
preservation of the peri-rectal fascia and the removal of the complete mesorectum. The 
technique of TME is based on sharp dissection under direct vision following the fascial 
surface of the mesorectum. This plane is usually avascular and enables identification and 
preservation of the autonomic nerve plexus [7]. 
The TME technique has been widely accepted as state of the art, although the surgical 
approach in colon cancer surgery has not received the same attention compared with rectal 
cancer. However, the issue of the different anatomical approach in rectal cancer compared 
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to colon cancer surgery has been addressed in recent years. In an attempt to further 
improve results, Complete Mesocolic Excision (CME), has been proposed in colon cancer 
surgery, in line with the surgical principles implemented in rectal cancer surgery [8] . 
Considering these facts, results have improved through centralised surgery to specialised 
colorectal units.  Modern surgical technique, preserving the fascias and peritoneal margin 
of the resection (mesorectum in rectal cancer and the segmental mesocolon in colon 
cancer), high-ligation of artery and vein are most likely key aspects in this development. 
And most importantly, a multidisciplinary team of surgeons, oncologists and pathologists 
that are participating in the pre- and postoperative treatment decisions.  
Survival and Prognosis 
Staging Systems 
Preoperative evaluation of newly diagnosed colorectal cancer (CRC) primarily relies on 
radiological investigation and postoperative classification of anatomic distribution of 
disease that is based on the International Union Against Cancer (UICC-TNM) and 
American Joint Committee on Cancer (AJCC) classifications [9,10]. Tumour depth, lymph 
node involvement, generalized metastases and tumour differentiation are still the most 
important morphological prognostic factors.  
Current recommendations suggest that Magnetic Resonance Imaging (MRI) should be 
used in assessing the depth of tumour invasion in rectal cancer in order to correctly 
evaluate the need for preoperative radiotherapy in patients with rectal cancer [1]. However, 
MRI was not standard of care in the preoperative evaluation during the period the patients 
in this thesis were included (1999-2004). 
The anatomy of the large intestine in relation to tumour classification 
The bowel wall is defined by following layers; the mucosal layer (epithelial cells and 
basement membrane, lamina propria and muscularis mucosa), the submucosa, the external  
 
Fig. 1. 
Tumour depth is 
displayed as the 
TNM(T) classification. 
T1 tumours are limited 
to the submucosal 
layer, where as T4 
tumours are 
characterized by 
tumour growth beyond 





muscle layer and the peritoneal (serosa) outer layer facing the abdominal cavity. These 
anatomical structures are the basis for the current staging systems in use (Fig. 1). As the 
depth of tumour invasion increases, the risk for nodal and distant metastasis increases.  
The investigation of the resected specimen defines the 3 N categories: N0 (no lymph nodes 
involved), N1 (1–3 lymph nodes involved), and N2 (>3 lymph nodes involved). Current 
guidelines recommend the identification of 12 or more lymph nodes in the resected 
specimen [11], as the examination of fewer regional lymph nodes has been associated with 
stage migration and subsequent poorer outcome in patients both with node-negative and 
node-positive disease [12,13]. 
It is generally believed that the examination of fewer lymph nodes may reflect an 
insufficient surgical procedure or a qualitatively poor pathological examination of the 
specimen. This can lead to an incorrect under-staging, thereby excluding the patient from 
beneficial adjuvant treatment. 
The TNM classification is the base for the UICC and AJCC classifications, which are often 
used in the clinical practice (Table 1).  
Table 1. The UICC-classification in relation to the 
TNM-classification Prognosis 
Despite improvements in surgical 
techniques, adjuvant and neo-adjuvant 
chemotherapy, the 5-year survival rate for 
patients with CRC ranges from 5-90% with 
tumour progression (stage I: 90-95%, II: 
75-85%, III: 50-60% and IV: 0-10%). The 
prognosis for patients without distant 
metastatic disease varies from 50-95% 
depending on the tumour stage [14].  
The correct staging of each patient is crucial in order to plan an optimal treatment regimen. 
It is widely recognised that prognostic information based on clinical and histopathological 
investigation is insufficient, although tumour stage and lymph node involvement are the 
main prognostic tools in evaluating cancer specific survival. It is questionable to expose a 
large number of patients to adjuvant treatment with considerable side effects without 
indications that they will benefit from such treatment. Finding molecular markers to better 
identify patients with higher risk for poor survival [15,16] would be valuable in order to 





ADJUVANT TREATMENT  
Background 
The principal treatment for colorectal cancer is surgery. The role of chemotherapy is 
mainly in the adjuvant setting and has a modest effect in colorectal cancer. Fluorouracil (5-
Fu) is the primary systemic treatment for colorectal cancer. It is a fluorinated pyrimidine 
which inhibits thymidylate synthetase, the rate-limiting enzyme in pyrimidine nucleotide 
synthesis [17]. 5-Fu is commonly combined with leucovorin (LV), which is believed to 
enhance the interaction of 5-Fu with this enzyme [18,19]. Pooled analysis of several 
randomized trials of postoperative fluorouracil-based therapy versus surgery alone have 
shown an increase in 5-year disease-free survival from 42% to 58% and a 5-year overall 
survival from 51% to 61% in patients with stage III disease [20]. It has also been shown 
that the addition of levamisole to fluorouracil and leucovorin does not improve survival 
[21,22]. Oral fluoropyrimidines have been evaluated in the adjuvant setting in colon 
cancer, and are effective in stage III colon cancer [23]. In a large randomised study 
(MOSAIC) in stage III colon cancer patients, treatment with either 5-Fu/Leucovorin (FLV) 
alone or with the complement of Oxaliplatin was compared. The study suggested a nearly 
9% increase in disease free-survival with the addition of Oxaliplatin to the FLV regimen 
[24]. 
Irinotecan (Campto™) has shown to be of value in patients with metastatic disease [25,26]. 
However, in the adjuvant setting, irinotecan has shown increased side-effects without 
improved results [27]. Other treatment modalities under current investigation are 
angiogenesis inhibitors (bevacituzimab (Avastin™)) and epidermal growth factor receptor 
inhibitors (i.e. Cetuximab (Erbitux™)). However, the role of these modern 
chemotherapeutic agents in the adjuvant setting is unclear and currently under 
investigation [28]. 
The adjuvant treatment of rectal cancer has mainly been based on the studies made in 
colon cancer patients, and level I data has been scarce, although sufficient amount of data 
exist regarding neo-adjuvant radiotherapy and radiochemotherapy [29]. During the current 
study period (1999-2004), 5Fu/Leucovorin was standard of care, and only patients with 
distant metastatic disease in the current studies have received irinotecan or oxaliplatin as 
palliative treatment. Forty-eight percent of colon cancer patients and 56% of rectal cancer 
patients that were UICC stage III in our studies received adjuvant chemotherapy. 
Use of adjuvant treatment for stage II colorectal cancer 
For patients with stage II colon cancer, the use of adjuvant chemotherapy remains 
controversial, but may be appropriate in a subset of individuals at higher risk for disease 
recurrence. An increased risk is expected in T4 staged tumours, tumours with bowel 
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perforation or if the analysis of the number of investigated lymph nodes is incomplete in 
the resected specimen [12,30]. Data from a large Scandinavian study during 1991-1997 did 
not support adjuvant treatment of stage II colorectal cancers [31]. At this time, the national 
Swedish treatment program for colorectal cancer does not support the general use of 
adjuvant chemotherapy in stage II colorectal cancer [1]. 
PROGNOSTIC MARKERS 
The evaluation of future risk for recurrent disease and subsequent poor survival of newly 
diagnosed colorectal cancer relies predominantly on staging that is defined by the UICC-
TNM and AJCC classifications. However, the specificity of information based on clinical 
and histopathological investigations is insufficient to fully estimate the risk for recurrence 
and poor disease specific survival. Selected patients without lymph node metastasis are 
likely to benefit from adjuvant chemotherapy, but cannot be properly identified.  
The UICC and AJCC classifications remain gold standard in predicting the outcome in 
colorectal cancer.  
In recent years numerous studies have addressed the issue of the quality of the pathological 
report. The number of investigated lymph nodes is of importance in order to correctly 
define the TNM classification in each patient [12]. In line with these findings, also the 
lymph node ratio (the number of cancer positive lymph nodes/the number of identified 
lymph nodes; LNR) has also been shown to perhaps more accurately identify patients with 
risk of poor prognosis compared with the traditional N-stage, where only the presence and 
number of cancer positive lymph nodes are evaluated [13]. At present, LNR is only used in 
the research setting, although its use might increase in clinical practice in the future. 
 
Molecular prognostic markers 
Many serum biomarkers are associated with disseminated disease, and the association with 
disease specific survival is less pronounced in the subgroup of patients without distant 
metastasis at the time of surgery [32]. Finding molecular markers to identify high-risk 
patients early would be valuable to be able to optimise treatment, but how these patients 
are best identified is not well understood [16,33]. 
Carcinoembryonic Antigen 
The utility of the Carcinoembryonic Antigen (CEA) as a prognostic factor has been under 
rigorous investigation during the last decades. The clinical value of CEA has been 
carefully evaluated, and results indicate that CEA is useful primarily in identifying patients 
with recurrent disease after curatively intended surgery during follow-up [9]. Results have 




It is believed that 75-80% of microsatellite stable (MSS) colorectal tumours arise from a 
pathway defined by aneuploidy, allelic losses, amplifications, translocations and mutation 
of APC, K-ras and P53. The prognosis of MSS colorectal cancer is dependent on TNM 
stage, although the prognosis for tumours belonging to the same UICC stage differs 
considerably. The remaining tumours are characterised by microsatellite instability (MSI), 
which is defined by inactivation of mismatch repair genes. The mutations of these genes 
are also associated with the loss of the Transforming growth factor-β1 (TGF-β1) receptor 
[37]. As TGF-β1 with increasing tumour load has an oncogenic effect, better survival in 
patients with MSI tumours compared with patients with MSS tumours is linked to the 
dysfunction of the TGF-β1 receptor [38]. However, these results are derived from 
retrospective studies, and the benefit of MSI status in clinical use is not defined.  
LOH18q 
The long arm of chromosome 18 contains important genes in colorectal cancer 
pathogenesis. Chromosomal loss at 18q has been associated with up to 70% of CRCs. The 
chromosomal loss is believed to be one of the corner stones of the adenoma-carcinoma 
sequence, although this model is increasingly debated [39]. The DCC gene, which maps to 
18q21 and codes for a neutrin-1 receptor, is believed to be a key player in colorectal 
carcinogenesis due to its role in apoptosis. The chromosomal loss at 18q is associated with 
shorter survival [40]. However, chromosomal loss as a useful prognostic marker in 
evaluating the risk for poor survival has not proved valuable in clinical practice.  
P53 
The P53 tumour suppressor gene has been under investigation for many years. 
Approximately 50% of colorectal tumours have mutations in the P53 gene, which has been 
associated with poor survival. However, the prognostic value of P53 has not been clinically 
meaningful and it is not recommended for either prognostic use or disease surveillance [9]. 
Tumour immunity 
Various immune/inflammatory cells, usually along the invasive margin, infiltrate human 
colorectal cancer tissues. However, results indicate that these cellular responses, 
particularly lymphocytic reactions, are independent prognostic factors for survival. 
Lymphocytes are recognised as small round cells by Htx-Eo stained sections. However, 
these cells are usually differentiated from plasma cells, neutrophils, eosinophils, 
macrophages or mast cells by their histological features. One of the pioneering works by 
Jass et al demonstrated, that infiltration by lymphocytes along the invasive border of rectal 
cancer is an independent prognostic factor for improved survival [41]. These results 
indicate that the microenvironment of the tumour is of fundamental importance in tumour 
invasion and progression. Although tumour infiltrating lymphocytes (TILs) have been 
especially associated with MSI tumours [42], the prognostic value of TILs seems to be 
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restricted to MSS tumours [43]. This suggests a difference in the biological environment 
for rectal cancers compared to colon cancers, as MSI tumours primarily are seen in the 
proximal colon. Although interesting, the use of TILs is not recommended in clinical 
practice. 
THE ROLE OF EXTRACELLULAR MATRIX IN TUMOUR BIOLOGY 
To enable tumour progression and metastasis, the tumour has to invade anatomical tissue 
borders, such as basal membranes and the interstitial stroma (Fig. 2). For tumour invasion 
to occur, extracellular matrix has to be degraded, and proteolytic enzymes mediate this  
 
process. Extracellular matrix-
degrading proteolytic enzymes can 
be divided into four subgroups 
according to their amino acid 
residue or cofactor required for 
catalytic activity: cysteine prote-
ases, aspartic proteases, serine 
proteases and metalloproteinases, 
which contain a metal ion in the 
catalytic site [44]. The serine 
proteases and metalloproteinases 
are discussed in this thesis. 
 
Fig. 2. 
The Extracellular matrix (ECM) is composed of the interstitial 
matrix and the basement membrane (BM). 
Proteases are produced in different cell types, such as tumour cells, fibroblasts, tumour-
associated monocytes and polymorphonuclear lymphocytes [45,46]. Cancer cells usually 
can modify their environment by producing stroma-modulating growth factors. The 
interplay between the tumour and the desmoplastic stroma is believed to play an important 
role in enabling tumour invasion and metastasis. Growth factors associated with 
extracellular stroma remodellation are fibroblast stimulating growth factor (FGF), 
members of vascular endothelial growth factor (VEGF), platelet derived growth factor 
(PDGF), epidermal growth factor receptor ligands (EGFR), interleukins and transforming 
growth factor-"1 (TGF-"1). These factors also activate surrounding stromal cell types, 
such as fibroblasts and smooth-muscle cells [47].  
 
Collagen are sub typed into several groups, type I, II, III and IV being the most common. 
Collagen type IV is the main component of the basement membrane (BM) [48], which is 
important in tumour invasion [49]. The BM consists of the outer layers; lamina 
fibroreticularis and lamina lucida and the inner layer (lamina densa). The structure of the 
BM has been debated, but electron microscopic investigation techniques have been useful 
in describing the three layers composing the BM [50]. 
Laminin, fibronectin, proteoglycans and glycosaminoglycans are other major glycoproteins 
in the extracellular matrix [51]. The functional overlap of the MMPs is significant. 
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Therefore, it is widely accepted that the complete range of MMPs can degrade all ECM 
components [48]. The MMPs are secreted as inactive pro-enzymes and activation is needed 
in order to achieve proteolysis [45].  
In summary, degradation of extracellular matrix is needed for cell migration and tumour 
invasion. Serine proteases and their inhibitors and especially MMPs are believed to be an 
essential part of this dynamic process. 
Regulatory components of the extracellular matrix 
Plasminogen/Plasmin System 
Fibrinolysis depends on the balance between the members in the plasmin/plasminogen 
system (PPS). In order to initiate fibrin degradation, inactive plasminogen has to be 
activated to plasmin. There are two different types of plasminogen activators, tissue-type 
(t-PA) and urokinase (uPA) plasminogen activator, that catalyses the conversion of the 
inactive precursor plasminogen to the active proteinase plasmin. Plasmin can degrade most 
extracellular proteins through activation of matrix metalloproteinases (MMPs). In the 
systemic circulation this is achieved by t-PA while the uPA system controls degradation of 
extracellular matrix primarily in tissue, which is important for tissue remodelling.  
uPA is a 52 kD serine proteinase that binds to a specific cell surface receptor (uPAR). The 
importance of uPA in relation to tumour growth has been shown in several different 
cancers and is reported to be associated with poor prognosis [52-56]. 
Plasminogen activator inhibitor-1 (PAI-1) is a member of the serine proteinase inhibitor 
(SERPIN) family and is the primary physiological inhibitor of both t-PA and uPA [57]. It 
circulates as a complex with the adhesive glycoprotein vitronectin [58]. The binding of 
uPA to uPAR stimulates intracellular signalling and is associated with cell adhesion [59]. 
PAI-1 is a 45 kDa serine proteinase, which acts as a fibrinolytic inhibitor [60]. It has been 
associated with tumour dissemination and poor prognosis in several tumour forms [61-64], 
opposed to its originally assumed role [65-67]. Additional mechanisms by which PAI-1 
can regulate tumour growth is by stimulating cell migration and apoptosis [68,69]. 
Paradoxically, a high level of PAI-1 in tumours has been shown to be an unfavourable 
prognostic factor [70,71]. 
Matrix metalloproteinases 
The matrix metalloproteinases (MMPs) are a group of Zn2+ or Ca2+ dependent proteases, 
whose function is to degrade components of the extracellular matrix. At least 28 MMPs are 
identified, of which 6 are transmembranous. The fibrinolytic system is, by the activation of 
MMPs through active plasmin, key players in the progression of different malignancies 
[44,72-77]. MMPs belong to a large family of proteinases, which can degrade different 
components of extracellular matrix, e.g. collagens, proteoglycans, laminins and 
fibronectins. These in turn are inhibited by three different “tissue inhibitors of 
metalloproteinases” (TIMPs). The MMPs are involved in extra cellular stromal breakdown 
8
 9 
in both pathological and normal situations. Previously MMPs were thought to be important 
in invasion and metastasis mainly by the degradation of the basement membrane and the 
ECM. It is evident that the role of MMPs is not restricted to degradation, but MMPs have 
also important roles in the activation of a number of cytokines, including growth factor 
precursors and receptors, tyrosine kinase receptors, cell adhesion molecules and other 
proteases that modify tumour environment [45]. 
Transforming growth factor-β1 
Transforming growth factor-β1 (TGF-β1) is a dimeric polypeptide belonging to a large 
family of related proteins [78-83]. TGF-β1 can be activated by cell-bound matrix 
metalloproteinases, and regulates tumour invasion and angiogenesis [84,85]. TGF-β1 
controls proliferation and differentiation in many cell types [86]. TGF-β1 has also a role in 
preserving epithelial tissue organisation, preventing early transition from organised 
hyperplasia to dysplasia and thereby inhibiting early stage tumorigenesis [87]. However, 
TGF-β1 appears to have the opposite function in more advanced tumour stages, as changes 
in TGF-β1 expression and signalling seems to promote tumour progression. These findings 
are usually explained as the dualistic character of TGF-β1, where the suppressor functions 
of TGF-β1 are found in early tumorigenesis and the oncogenic effects are seen in a later 
(metastatic) phase of tumour progression [37]. The suppressor capabilities are derived, in 




AIMS OF THESIS 
The aims of the thesis were to: 
 
 Evaluate whether the expression of molecular markers capable of degrading 
extracellular matrix covariates with known tumour staging classifications. 
 
 Evaluate the prognostic associations measured as cancer specific survival of these 
markers in colorectal cancer. 
 
 Evaluate whether the prognostic association of these markers differs between colon 
and rectal cancer. 
 
 Evaluate whether any of these markers can identify individuals with high risk of 
disease specific death after curative surgery. 
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MATERIAL AND METHODS  
PATIENTS 
Study patients 
Patients with colorectal cancer were prospectively included between 1999-2004.  Patients 
who received neo-adjuvant radiotherapy due to rectal carcinoma where excluded as 
irradiation causes a local reaction in the tissue marked by inflammation and thus is a 
confounding factor when assessing the expression of tissue remodelling proteases [89,90]. 
The total number of patients included was 221 (colon cancer n=156, non-irradiated rectal 
cancer n=65). None of the participating patients in the studies had neo-adjuvant 
chemotherapy in accordance with the institutional treatment protocol. All patients received 
one standardised dose of prophylactic antibiotics and prophylaxis against thrombosis with 
low-molecular-weight heparin. Informed consent was obtained from all included patients, 
and the studies were approved by the local Ethics Committee. 
Non-study patients during the time period 
Rectal cancer 
The exclusion of subjects who received radiotherapy could have introduced selection bias. 
An analysis was therefore undertaken to assess the magnitude of this potential effect. One 
effect is that there are more patients with disseminated rectal cancer in the study 
population, as they are not eligible for pre-operative radiotherapy. Furthermore, based on 
eligibility criteria for radiotherapy one would expect that there was a divergent distribution 
of T-stage between the irradiated and the non-irradiated population. Patients that received 
preoperative radiotherapy were included in other studies during the same study period and 
were compared with patients included in this thesis. Much to our surprise, the two 
populations were comparable in terms of T-stage distribution (unpublished data). It is 
therefore reasonable to assume that the results obtained in the population we investigated 
could be generalisable. However, results also suggest that the pre-operative selection of 
patients for preoperative radiotherapy during the study period might have been inadequate.  
 
During the study period, a total of 344 subjects with rectal cancer were not included in the 
studies, and 223 of these subjects did not undergo radiotherapy. To investigate how this 
could influence conclusions, we compared characteristics of this population with the study 
population. The information that was available on the non-study patients was UICC stage. 
No significant differences were observed in UICC distribution between patients included 
in the studies compared to patients outside the studies at our centre during the study period. 
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This means that about 2/3 of all patients did not take part of the study. No significant 
differences were observed in UICC distribution between patients included in the studies 
compared to non-study patients during the study period. 
Colon cancer 
Information on non-study patients was not available in patients with colon cancer. Instead, 
demographic data from all patients surgically treated at the Department of Surgery, 
Sahlgrenska University Hospital/Ostra during the study period were analysed. A total of 
649 patients with colon cancer had their tumour surgically resected. Therefore, about 2/3 
of all patients did not take part of the study. No significant differences were observed in 
UICC distribution between patients included in the studies compared to all patients treated 
at the surgical department during the study period.  
Paper I 
Seventy-two patients who underwent surgery for a colorectal carcinoma were included in 
the study between February 1999 and September 2000. The average age of the patients 
with rectal cancer was 74 years and 72 years for patients with colon cancer. The average 
age of all patients was 73 years.  
Paper II and IV 
A cohort of 169 patients who underwent surgery for a colorectal carcinoma between 
February 1999 and June 2003 were prospectively included in the study. The mean age of 
patients with colon cancer was 73 years (range 42-91) years and for rectal cancer patients 
75 years (range 51-89).  
Paper III 
A cohort of 221 patients who underwent surgery for colon and rectal cancer during the 
period February 1999 to March 2004 was prospectively included.  
The mean age of colon cancer patients was 72 years (range 31-93) and 75 years (range 38-
89) for patients with rectal cancer. Eighty-one (52%) of the patients with colon cancer 
(n=156) and 37 (56%) of rectal cancer patients (n=65) were males.  
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TISSUE SAMPLING & PROCESSING 
Optimising blood and tissue sampling: the pilot study 
Before commencing the study we performed a pilot study including 5 patients with 
colorectal cancer. The results demonstrated that biopsies had to be processed immediately 
for mRNA assessment. mRNA degraded if the biopsy was obtained on average 40 minutes 
after resection, compared to immediately after resection. However, protein quality seemed 
unaffected by the delay (unpublished data). Strict biopsy retrieval and placement of the 
biopsies in liquid nitrogen was therefore employed in the studies. A sample setup was 
prepared and in place in the operating theatre through all the studies in order to minimise 
the risk for tissue degradation. 
Blood samples 
Blood samples were taken in a standardised way after induction of anaesthesia.  
In order to minimise platelet-associated contamination, citrate tubes were utilised for 
sample collection, as the use of EDTA tubes can be associated with increased platelet 
associated contamination [91-93]. Venous blood was collected in sodium citrate 
and Diatube (CTAD), (BD, Franklin Lakes, NJ, USA) tubes, then centrifuged and the 
supernatant frozen at –80°C until assayed. 
Tissue samples 
Surgical biopsies were taken immediately after resection in the operating theatre. Each 
biopsy measured approximately 1 cm2. Three biopsies were taken from each patient. One 
biopsy was taken from the macroscopically tumour-free bowel segment, approximately 10 
cm from the tumour, and a second biopsy from the tumour itself. The necrotic tumour 
centre was avoided during the biopsy procedure. The tissue samples were snap frozen in 
liquid nitrogen in the operating theatre. A third biopsy was taken from the macroscopical 
tumour borderzone for immunohistochemical assay and put in Bouin’s solution.  
TISSUE AND BLOOD PROCESSING 
After thawing, samples were weighed and homogenised using an Ultra-Turrax (24 000 
rpm) in PBS buffer containing 0.01% Triton X-100 using 1 ml buffer per 40 mg of tissue. 
The homogenate was centrifuged (10 000 g, 3 minutes) and the supernatant collected and 
frozen at –80°C until assayed for protein as previously described [94].  
The number of operators was kept to a minimum to standardise the procedures. Two 
operators did all homogenisations and protein extractions. 
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Protein analysis  
Enzyme-linked immunosorbent assay (Paper I-IV) 
Commercially available enzyme-linked immunosorbent assay (ELISA) was used to detect 
and quantify analysed proteins. The antigen is attached to pre-coated plates and excess 
antigen is washed. A secondary antibody specific for the antigen together with a linked 
enzyme is then attached to the plate. By using an antibody-antigen reaction, as well as an 
enzyme reaction, this technique converts a peroxidase sensitive substrate into a colour. The 
absorption at a specific wavelength was quantified by spectrophotometer (V-max, 
Molecular Devices) to measure concentration. Internal standards of known concentrations 
are used to quantify the optical densities of the samples. The principal mode of action of 
the ELISA is shown in (Fig. 3). 
Variability of the assays 
Experienced laboratory technicians performed the assays and all samples were analysed in 
duplicates. To minimise inter-assay variability, two operators performed the assays. 
Quality control of the assays included samples with known concentrations and a reagent 
blank on each plate. Further, each plate had several control samples with known 
concentrations, that were used in several ELISA plates in order to evaluate inter-assay 
variability. To standardise the results, the concentrations of measured markers were 
normalised to the total protein content of each sample [95]. Assays of total protein content 
were performed using a chromogenic assay (DC Protein assay, Bio-Rad Hercules, CA, 
USA). 
 
Intra- and inter-assay variations 
Intra-assay variations are variations 
between samples within the same ELISA 
plate and inter-assay variations are 
variations between the analysed plates. 
These variations are defined as the 
product of the standard deviation divided 
by the mean (the coefficient of variation) 
expressed as %. According to the 
manufacturer, the intra-assay variations 
for uPA and PAI-1 were below 9%, for 
MMPs between 3-7%, and for TGF-!1 
4%. Similarly, the inter-assay variations 
for uPA and PAI-1 were 5-8%, MMPs 6-
9% and 11.6% for TGF-!1. In our 
laboratory similar or lower intra- and 
inter-assay variations were observed. 
Fig. 3. 
The mode of action for the enzyme linked immuno-
sorbent assay (ELISA) is characterised by the use of 
several specific antibodies to measure protein 
concentration. After the application of the horseradish 
peroxidase (HRP) linked antibody, substrate 
(tetrametylbenzidine, (TMB)) is added and the 
absorption is quantified by spectrophotometer. 
Illustration in co-operation with MD E Angenete. 
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Immunohistochemistry (Paper IV) 
Biopsies taken from the borderline of the tumour and the adjacent tumour free mucosa 
during surgery were fixed overnight in Bouin’s solution (Sigma Diagnostic, St Louis, MO, 
USA). Following wash with phosphate buffered saline solution biopsies were dehydrated 
in increasing ethanol gradients and xylene prior to paraffin fixation. Sections (4-6 µm) 
were deparaffinised and stained with Haematoxylin & Eosin for morphologic assessment. 
For immunological evaluation antibodies towards MMP-1 were examined. Primary mouse 
antibodies against human MMP-1 diluted to 1 µg/mL (#IM35L, 1:100, Calbiochem, 
Oncogene Res Products, Cambridge, MA, USA) were used together with the DAKO 
Envision system (DAKO Cytomation, Glostrup, Denmark). The signal was detected with a 
chromogenic substrate (diaminobenzidine) according to the manufacturers instructions. A 
negative control consisted of incubations of tissue sections with mouse IgG directed 
towards an enzyme that is neither present nor inducible in mammalian tissues (X-0931, 
DAKO Cytomation, Glostrup Denmark). Counterstaining with Haematoxylin-Eosin was 
used prior to dehydration and mounting with cover slips. Evaluation of distribution and 
qualitative comparison was performed using Nikon Eclipse 50i microscope together with 
Nicon Eclipse E1000M and Kontron Elektronik/Prog/Res/3012 digital photo equipment. 
STATISTICS 
Paper I 
Due to the limited number of patients in the different stages, non-parametric tests were 
used, as a non-normal distribution was assumed. Friedmans test was used regarding 
comparison between tumour tissue, plasma and tumour free tissue. Kruskal-Wallis test was 
used in the analysis of more than two variables and Mann-Whitney U-test for analysing 
differences between two groups. A p-value of less than 0.05 was accepted as significant. 
All graphs were presented as Box-plot showing the median (horizontal line), interquartile 
range (boxes) and 10th and 90th percentiles (error bar). 
Paper II 
As the patient cohort was larger, a normal distribution was assumed. When comparing 
multiple groups, an ANOVA including Fishers’ protected least significant difference 
(PLSD) correlation for multiple comparisons was used. Analysis of differences between 
tumour biopsy specimen and tumour-free bowel segments was performed with the paired t-
test. A p-value of less than 0.05 was accepted as significant. All graphs were presented as 
Box-plots showing the median (horisontal line), the interquartile range (boxes) and the 10th 
and 90th percentiles (error bar). 
Paper III-IV 
The findings in paper II indicated that there might be differences in the expression between 
colon and the rectum. Therefore, patients in paper III and IV were analysed in relation to 
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tumour site (colon or rectum). The number of patients in the smallest group (rectum n=47 
in paper IV and n=65 in paper III) necessitated non-parametric statistics, as the patient 
group was limited. 
The Wilcoxon signed rank test was used for related samples and the Mann-Whitney U test 
was used for the analysis of independent parameters.  The Cox proportional hazard method 
was used for uni- and multivariate analysis to determine the prognostic value of the 
measured markers. Hazard ratio (HR) was displayed with a 95% confidence limit (CI 95%) 
and p-values less than 0.05 were considered significant. The number of investigated 
variables in the multivariate analysis was in coherence with the number of events (deaths) 
in each study. The Kaplan-Meier method and Log rank test was used to compare the 
survival curves in relation to chosen cut-off values. Optimal cut-off values were identified 
by Receiver Operating Characteristics curves (ROC curves). 
Graphs were presented as box-plots showing the median (horizontal line) interquartile 
range (boxes) and the 10th and 90th percentiles (error bars). Statistical analysis was carried 
out with SPSS 13.0 (SPSS Inc., Chicago, Illinois, U.S.A.) 
Aspects on multiple testing 
Multiple analyses, as performed in the papers in this thesis, are subject to the risk of mass-
significance. An exception is the Fishers’ PLSD test used in paper II, where multiple 
comparisons are taken into account. In theory, multiple testing will by chance alone make 
every twentieth test significant at the 5% level. Multiple comparisons can also be 
compensated for by using the Bonferroni correction or by adjusting the p-value to a value 
lower than 0.05. However, using a correction increases the risk of not discovering results 
through a beta-error. It remains controversial whether a Bonferroni correction is necessary 
or not. Using this type of correction may be considered statistically conservative. The 
Bonferroni method was not used in the current thesis, but an awareness of the number of 
analyses was a key aspect when interpreting the results. In particular, this would be 




RESULTS & DISCUSSION 
A prognostic marker is defined as a quality associated with prognosis or outcome, usually 
in terms of relative hazard of failure, whereas a predictive marker is defined as a quality 
that is associated with, and predicts, treatment response. This thesis addresses markers of 
tissue remodelling and their association with disease survival and tumour progression. 
Although the TNM classification is the most accurate prognostic tool available, it is 
insufficient in identifying all patients with poor prognosis with colorectal cancer. 
Therefore, identifying possible prognostic markers has been of major interest and subject 
to extensive research. Despite several decades of translational research and many areas 
showing promising results, no biochemical markers are presently in use.  
 
However, the most significant development in recent years has been achieved in the area of 
predictive markers. K-ras mutation status has been associated with improved treatment 
response in metastatic colorectal cancer. The background of these findings are that 
mutations of K-ras in the corresponding kinase pathway can lead to constant activation of 
the epidermal growth factor receptor (EGFR), which can lead to resistance to EGF 
antibodies [96]. Recent results have shown that selection of patients with metastatic 
colorectal cancer for treatment with EGFR antibodies, (cetuximab or panitumumab), is 
depending on the K-ras status of the tumour. Both response to panitumumab monotherapy 
and improvement in progression-free survival were restricted to patients with wild-type K-
ras [97]. However, the association of K-ras status and EGFR treatment in the adjuvant 
setting with improved survival in stage III patients is unclear.  
Matrix metalloproteinases in colorectal cancer (Paper I and IV) 
Several studies indicate that many MMPs are over expressed in colorectal tumours, and an 
increase in protein expression is correlated to an advanced Dukes’ stage and to decreasing 
tumour differentiation [98-100]. At which time-period during tumour progression the 
MMPs are of most importance has been under debate. Accumulating data show the 
importance of MMPs in the early transition from a localised tumour to an invasive cancer 
[101]. As the MMPs have an essential role in degrading the basement membrane, special 
interest has been placed on MMP-1 and the gelatinases (MMP-2 and MMP-9), as they 
together are capable of degrading the collagen components of the BM. An increasing 
amount of evidence show that MMPs are associated with tumour progression and invasion 
[98-100,102,103]. Increasingly, research data indicate that the MMPs have functions other 
than promotion of invasion, have substrates other than components of the extracellular 
matrix, and that they can have a function before invasion in the development of cancer by 
activating growth factors and cytokines [45].  
These considerations are in line with the results in paper I, as both MMP-1 protein 
expression in tumour tissue (Fig. 4) and MMP-2 expression in plasma (Fig. 5) were 
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associated with, not only increasing tumour stage (T-status), but also lymph-node 
metastasis in patients without distant metastatic disease (Fig. 6 and 7). 
  
Fig. 4. 
The MMP-1 protein expression in tumour tissue was 
significantly higher in T2 and T3 tumours compared 
to more advanced T4 tumours. Reprinted with 
permission of Springer-Verlag GmbH Heidelberg 
Fig. 5. 
The MMP-2 protein expression in plasma was 
significantly higher in T2 and T3 tumours 
compared to T4 tumours. Reprinted with permission 
of Springer-Verlag GmbH Heidelberg 
  
Fig. 6. 
The MMP-1 protein expression in tumour tissue was 
significantly higher in patients with lymph node 
metastasis, but without distant metastatic disease. 
Reprinted with permission of Springer-Verlag GmbH 
Heidelberg. 
Fig. 7. 
The MMP-2 protein expression in plasma was 
significantly higher in patients with lymph node 
metastasis, but without distant metastatic disease. 
Reprinted with permission of Springer-Verlag 
GmbH Heidelberg. 
 
The association of MMP protein expression with advancing T-stage and lymph node 
metastasis in paper I was interesting, as the results simultaneously suggested that both low 
protein expression of MMP-1 in tumour tissue and low MMP-2 in plasma was associated 
with metastatic disease. These results are supported by Waas et al. who showed that low 
systemic MMP-2 (ELISA) and active MMP-2 expression were associated with metastatic 
disease [104], and this correlation was also observed in tumour tissue [105]. However, 
contradictory data exist and could perhaps be explained by different bioassays utilised to 
assess the expression [106].  
The association of MMP-1 in tumour tissue and MMP-2 in plasma with tumour stage 
indicated that these factors could possibly be associated with survival. The finding in paper 
IV that MMP-1 and -9 expression in adjacent tumour free mucosa was associated with 
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cancer specific survival was an unexpected finding (MMP-1 mucosa; p=0.001, HR: 1.13, 
CI: 1.05-1.21 / MMP-9 mucosa; p<0.002, HR: 1.11, CI: 1.04-1.19). 
The most encouraging result was that MMP-1 in tumour free mucosa maintained its 
association with CSS in patients without distant metastatic disease in both uni- and 
multivariate analysis. An interesting aspect of these findings was that the prognostic 
information that would be available in the postoperative pathology report might be 
available in the preoperative setting through a mucosal biopsy. The results in paper IV 
indicate that the MMP-1 expression in tumour free mucosa can identify patients without  
 
distant metastatic disease with high risk of 
poor survival to the same extent as nodal 
status in patients with colon cancer (Fig. 
8). An interesting question would be if 
MMP-1 expression in tumour free mucosa 
was able to identify stage II patients at 
risk of poor survival, as current tumour 
classifications are insufficient in the risk 
evaluation in these patients. However, the 
number of events (deaths) in this subgroup 
of patients did not allow the analysis to be 
done from a statistical point of view. 
 
The interplay of the tumour with the 
surrounding non-tumourous stroma was 
visualised by immunohistochemistry in 
paper IV, where activated fibroblasts in 
the tumour-free stroma in the immediate 
vicinity of the invasive zone, showed high 
MMP-1 immunoreactivity (Fig. 9). This 
Fig. 8. 
The survival curves are displayed for patients without 
distant metastasis, stratified by N-status (N0/N1-2) and 
high (>0.7 ng/mg) and low (<0.7 ng/mg) MMP-1 
protein expression in tumour free tissue. Patients 
without lymph node metastasis (N0) had a better 
outcome compared to patients with lymph node 
metastasis (N1-2). Similar survival curves were 
observed when patients were stratified for the MMP-1 
cut-off level. Patients with high MMP-1 expression in 
tumour free tissue had a significantly worse outcome 
compared with patients with low MMP-1 protein 
expression in tumour free mucosa (Log rank test). 
 
would indicate that matrix degradation had been activated in this zone. One might 
therefore speculate that the capability of the tumour to mobilise the proteolytic reserves of 
adjacent normal intestinal mucosa, could partly determine the risk of lymphatic invasion 
and subsequent metastasis. Although prognostic data regarding MMP-1 protein expression 
is limited, semiquantitative immunohistochemistry data indicate that MMP-1 expression 
also in tumour tissue could be associated with tumour invasion [107] and survival [108].  
As MMPs are believed to be important in the early phase of tumorigenesis and therefore a 
possible marker of disease progression, the lack of association between increasing tumour 
stage and poor survival with systemically measured MMPs has been disappointing. Results 
from Oberg et al showed limited clinical value of either MMP-2 or MMP–9 protein 
expression in serum for tumour staging or prognosis, although higher free MMP-2 
expression in sera was associated with shorter survival time [109]. Waas et al found 
similar results [104], and in a follow-up study where gelatinase expression was compared 
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with CEA, systemically measured gelatinases were not able to identify patients with 
recurrent disease during the follow-up period [110]. These results are in line with the 
results presented in this thesis, as survival data showed no association of systemically 
measured MMP-2 and -9 protein expression with cancer specific survival. Therefore, the 
association of higher MMP-2 expression in plasma in patients with lymph-node metastasis 
seen in paper I do not seem to be of clinical relevance. The proteolytic enzymes act locally 
in the stroma and systemic expression might be of no or limited informative value. 
 
Recent findings indicate that tissue 
concentration and immunohistochemical 
presence of MMP-2 protein expression in 
tumour tissue as well as in the surrounding 
stroma is associated with poor survival in 
univariate analysis [111,112]. The results 
in paper IV support these findings and 
there is increasing evidence that MMP-2 
expression in tumour tissue is associated 
with poor survival in patients with 
colorectal cancer. However, the finding 
that ELISA derived MMP-2 expression in 
tumour tissue is associated with survival 
only in colon cancer is to our knowledge 
not previously described, although recent  
Fig. 9. 
Reactive fibroblasts in the immediate vicinity of the 
invasive zone of the tumour are displayed by MMP-1 
immunoreactivity. 
 
immunohistological data suggest that epithelial tumour expression of MMP-2 might be of 
differential prognostic importance in colon and rectal cancer [112]. 
The plasminogen/plasmin system in colorectal cancer (Paper III) 
During the isolation and recognition of PAI-1, it was generally assumed that plasmin 
through the activation of plasminogen was the main pathway in which MMPs were 
activated and exerted their proteolytic effects during tumour invasion. This has also been 
the main hypothesis, namely that tumour progression and prognosis is associated with 
purely the degrading capacity of MMPs. In this system, the role of PAI-1 was thought to 
be purely inhibitory. Therefore, clinical results identifying PAI-1 expression with poor 
prognosis in several tumour forms, was an unexpected finding [56,62-64,113,114]. 
However, it has become apparent that the interplay of uPA, PAI-1 and the MMPs is 
complex, and that the initial assumption that the role of MMPs is limited to matrix 
degradation can be questioned. 
Results in vitro have previously shown that high PAI-1 concentrations have anticancer 
effects [115]. Previous results on a knockout mice model have shown that endogenous 
PAI-1 is needed for invasion, indicating that PAI-1 can have differential mode of action in 
cancer development. The binding of uPA to its membrane bound receptor is shown to 
enhance cell adhesion. However, a complex of not only uPA/uPAR, but also 
uPA/uPAR/PAI-1 is needed in order to achieve cell-detachment [116]. These results 
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describe a possible mode of action that could partly explain the unexpected primary 
results, i.e. PAI-1 being associated with poor prognosis in cancer. 
The results in paper III of high uPA in tumour free mucosa being associated with improved 
survival were unexpected. The Cox proportional regression analysis in paper III showed 
that higher uPA protein expression in tumour free mucosa was significantly associated 
with improved survival in rectal cancer (p=0.005, HR: 0.232, CI: 0.08-0.64). Also in 
patients without distant metastatic disease, low uPA concentrations in tumour free mucosa 
seemed to identify patients with increased risk of poor cancer specific survival (Fig. 10). 
These findings were also true for stage I and II patients, as the mucosal uPA expression 
below the cut-off level identified all deaths in this subgroup of patients. However, these 
results must be interpreted with caution, as the number of events in this subgroup of 
patients was low (n=8).  
 
 
The biological explanation for the 
association of uPA in tumour free mucosa 
with survival is unclear. However, a higher 
uPA expression in tumour free mucosa 
might reflect less complex formation, 
which might be associated with decreased 
cell detachment. It is possible that the 
expression of uPA in mucosa reflects a 
reduced invasive potential of the tumour. 
On the other hand, it is possible that the 
uPA expression in the intestinal mucosa is a 
marker for a different biological 
phenomenon. As white blood cells are 
known to harbour large amounts of uPA, 
the improved survival in patients with high 
uPA concentration could be associated with 
immunological aspects of tumour or host 
Fig. 10. 
Patients were stratified by the median uPA protein 
expression in tumour free tissue. Patients with high 
uPA protein expression in tumour free tissue had a 
significantly better outcome compared with patients 
with low uPA protein expression in tumour free 
mucosa (Log rank test). 
immunity [41,117]. Nevertheless, in accordance with the discussion regarding the 
prognostic association of MMP-1 and -9 in the adjacent tumour free mucosa, it is apparent 
that adjacent tumour free mucosa cannot be regarded as biologically normal. These results 
suggest that more general and basic changes in the intestinal mucosa are present in a 
tumour-bearing segment, and that these changes are of differential importance in the 
proximal and distal large intestine. 
The finding that PAI-1 in plasma was associated with cancer specific survival is consistent 
with previous reports [71]. Our results indicate that high PAI-1 in tumour tissue and 
plasma is associated with poor survival and that the inverse association pertains to uPA 
expression in tumour free mucosa. As shown in paper III, PAI-1 protein expression in 
plasma correlated to metastatic disease in patients with rectal cancer (p<0.0001, r=0.524, 
n=62), and was significantly higher (p<0.0001) in rectal cancer patients with distant 
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metastatic disease. This finding is consistent with the results of the Cox proportional 
hazard analysis, as the association of PAI-1 in plasma with survival was abolished when 
studied together with M-stage (multivariate analysis: M-stage: p<0.0001, HR: 20.59, CI: 
5.20-81.49 / PAI-1: p=0.72, HR 1.15, CI: 0.053-2.53). This suggests that the systemic 
expression of PAI-1 is associated with distant metastatic disease. As PAI-1 has been 
reported to act as an acute phase reactant [118], the association with poor survival might be 
an indication of a more generalised systemic response to distant metastatic disease rather 
than the tumour itself. Due to the exclusion of patients that received radiotherapy, the 
number of patients with metastatic disease was increased in rectal cancer group. This could 
have strengthened the prognostic association seen in rectal cancer compared with colon 
cancer. However, no association of uPA and PAI-1 expression with survival was seen in 
colon cancer, indicating a different tumour environment in colon and rectal cancer.  
It is conceivable that PAI-1 could be used in the follow-up of patients with rectal cancer 
after surgery with a curative intent in order to identify patients with recurrent metastatic 
disease. However, conclusions regarding this aspect cannot be addressed in the context of 
this thesis, but further studies addressing this issue seem warranted.   
Transforming growth factor-"1 in colorectal cancer (paper II and IV) 
There is increasing evidence that TGF-"1 has several functions, and exerts both tumour-
suppressive and oncogenic effects [37], and that TGF-"1 is strongly associated with the 
regulation of extracellular remodellation.  
  
Fig. 11. 
Significantly higher TGF-!1 expression in tumour 
tissue was seen in patients with colorectal cancer 
and distant metastatic disease (M1) compared with 
patients without distant metastasis (M0). Reprinted 
with permission of Wiley-Liss, Inc. a subsidiary of 
John Wiley & Sons, Inc 
Fig. 12. 
Significantly higher TGF-!1 expression in plasma 
was seen in patients with colorectal cancer and 
distant metastatic disease (M1) compared with non-
disseminated patients (M0). Reprinted with 
permission of Wiley-Liss, Inc. a subsidiary of John 
Wiley & Sons, Inc 
 
In paper II, increasing T-stage was positively correlated with higher TGF-"1 protein 
expression in tumour tissue (p=0.001, r=0.297). As the correlation could be due to the fact 
that T4 tumours are frequently associated with metastatic disease, a separate analysis was 
done, excluding patients with distant metastatic disease. However, the correlation remained 
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positive (r=0.237, p=0.001), indicating also a localised role of TGF-"1 in tumour invasion. 
Distant metastatic disease influenced total TGF-"1 protein expression, and total TGF-"1 
protein expression in both tumour tissue and plasma was significantly higher in patients 
with metastatic colorectal cancer compared to patients with non-metastasising disease (Fig. 
11 and 12).  
There are previous reports of higher TGF-"1 plasma and serum protein expression in 
patients with metastatic disease [119,120], which is further supported by the results in 
paper II. These studies indicated that TGF-"1 protein expression, although most 
predominantly expressed in patients with metastasising disease, also might be dependent of 
the local invasiveness of the tumour, as expression correlated with increasing T-status, 
(Fig. 13).  
 
 
Although TGF-"1 is tightly linked to MMP 
regulation, our results indicated a separate 
mode of action for these markers during 
tumour progression in colorectal cancer.  
Higher expression of TGF-"1 in patients 
with metastatic disease was supported by 
the results in the Cox proportional hazard 
analysis, which indicated that TGF-"1 
expression in tumour tissue was weakly 
associated with poor survival in both colon 
and rectal cancer. TGF-"1 concentration in 
plasma was significantly associated with 
CSS in rectal cancer patients. This 
association was not maintained in 
multivariate analysis due to the strong  
Fig. 13. 
TGF-!1 protein expression in tumour tissue was 
significantly associated with increasing T-status in 
patients with colorectal cancer. Reprinted with 
permission of Wiley-Liss, Inc. a subsidiary of John 
Wiley & Sons, Inc 
 
association to metastatic disease. The results in paper II suggested that local TGF-"1 
expression in tumour tissue could be of importance in evaluating tumour progression and 
subsequent worse survival. These findings were not supported by survival analysis, as no 
association with CSS and TGF-"1 expression was seen in patients without distant 
metastatic disease. However, the study by Tsushima et al where 5-year-survival was 
evaluated, high preoperative TGF-"1 protein expression in plasma was strongly predictive 
of recurrent disease manifested as liver metastasis after curative resection of colorectal 
cancer [121]. These results could not be confirmed in paper IV. A possible explanation is 
the different endpoints utilised. In the present studies CSS was evaluated in contrast to 
disease free survival used by Tsushima et al. Additionally, the exclusion of non-irradiated 
patients or a shorter follow-up period for the patients included in this thesis could partly 
explain the different results. 
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Aspects on the adjacent normal intestinal mucosa 
The observation that the expression of MMP-1 and MMP-9 in tumour free intestinal 
mucosa was associated with survival was an intriguing concept. However, a similar 
observation has previously been reported in subjects with gastric cancer [122]. An 
important question would be if these changes in adjacent, apparently normal mucosa 
precede tumour development or if they are a function of the presence of the tumour. The 
present thesis does not allow any conclusions in this matter. However, the results indicate 
that the presence of a tumour in the colon or rectum can be associated with more 
widespread biological changes in the large intestine.  
The immunohistochemical analysis in paper IV indicated that morphological differences in 
staining pattern in tumour free mucosa between colon and rectal cancers can be present. 
This could suggest a different biological tumour environment in colon and rectal cancer, 
supporting the divergent prognostic impact of MMP-1 in adjacent tumour free mucosa 
observed for these two types of cancer. The results from paper III also suggest that colon 
and rectal cancers could be regarded as two separate tumour forms, as the differential 
prognostic association with survival of uPA expression in mucosa was present. There are 
several reports regarding different cellular and expressional pattern in the adjacent normal 
mucosa in patients with a colon or rectal carcinoma [123-125]. Paper II indicated that 
TGF-β1 expression in tumour free mucosa in patients with colon cancer differs compared 
to rectal cancer patients. Recent results show two different gene expression patterns in the 
normal mucosa of the large intestine [126]. One pattern is consistent with the midgut-
hindgut embryonic origin, and another pattern displaying a gradual change in transcript of 
multiple genes along the large intestine.  
In summary, different molecular expressional profiles are likely to be present in the 
apparently normal mucosa of the proximal and distal colon. In addition, the adjacent 
normal mucosa expresses properties that have impact on the prognosis in colon and rectal 
cancer. Interestingly, this thesis also suggests that measured factors in normal mucosa of a 
tumour bearing segment that are capable of matrix degradation, are differentially 
associated with survival in colon and rectal cancer. 
Expressional and prognostic differences in tumour tissue in the proximal 
and distal large intestine 
Results in paper II indicated that TGF-β1 protein expression in tumour tissue was higher in 
colon cancers compared to rectal cancers (Fig. 14). Expressional data on both protein and 
mRNA level support these data, indicating a different tumour biology in the proximal and 
distal colon [127,128]. Results also suggest that uPA has a differential expression in the 
proximal and distal large intestine [129]. The concept that the colon and rectum represent 
two different entities from a tumour biology point of view is supported by evidence that 
two different genetic mechanisms, microsatellite instability (MSI) and chromosomal 
instability (CIN) contribute unevenly to the carcinogenesis in the different parts of the 
lower GI-tract [130,131]. The prognostic differences in the present study could possibly be 
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explained by these underlying mechanisms in the colon and the rectum. The effect of the 
exclusion of irradiated patients could have influenced results. However, the comparison to 
irradiated patients included in other studies during the same period indicate, that no T-
status migration is present between irradiated and non-irradiated rectal cancer patients 
(unpublished data). The reason for this 
 
distribution is unclear and might indicate a 
suboptimal selection of patients for 
preoperative radiotherapy. It is therefore 
reasonable to assume that the results 
obtained could be valid for all patients with 
rectal cancer. 
Aspects on prognostic information 
in different tissue compartments 
Results included in this thesis indicate that 
the association of systemically measured 
factors with survival is due to their strong 
correlation with metastatic disease. These 
findings might reflect, perhaps not a 
specific proteolytic mechanism, but rather a 
generalised response to metastatic disease 
Fig. 14. 
TGF-!1 protein expression in tumour tissue was 
significantly higher in patients with colon cancer 
compared with patients with rectal cancer. 
Reprinted with permission of Wiley-Liss, Inc. a 
subsidiary of John Wiley & Sons, Inc 
 
and inflammation. Previous research demonstrates that many markers are associated with 
metastatic disease, and that the association with disease survival decreases in the subgroup 
of patients without presence of distant metastatic disease [32]. 
 
However, in patients without metastatic disease, tumour free mucosa was most strongly 
associated with CSS. One would have expected that the essential prognostic information 
should have been found in tumour tissue. The reason for this might be found in tissue 
processing. The homogenisation of tissue has been commonly used in translational 
research. It is however conceivable that much of the prognostic value is diluted by this 
process, as one can assume that the majority of colorectal tumours are very heterogenic. As 
adjacent tumour free tissue had the most bearing on the postoperative prognosis in our 
studies, it could be hypothesised that a homogenic tissue compartment, such as tumour free 
mucosa or plasma, might give more solid prognostic data. 
 
In the future, it might be more appropriate to consider micro dissection as a tool for ECM 
tissue sampling, as specific stromal structures without contamination of tumour cells, can 
be chosen for further analysis. However, this would limit available analysing techniques, 
as protein detection requires a substantial amount of tissue. In principal, only Real Time 
Polymerase Chain Reaction (RT-PCR) techniques would probably be adequate 
investigational tools today, as a small amount of tissue is needed for mRNA evaluation. 
25
 26 
Tissue remodelling components and their biological role in tumour 
progression: Summary and conclusion 
In summary, TGF-β1 and PAI-1 protein expression indicate similar features in relation to 
tumour progress in colorectal cancer, as they were associated with distant metastatic 
disease. Both markers were associated with known pathological staging classifications and 
were over-expressed in both tissue and plasma in rectal cancer patients with metastatic 
disease. However, their prognostic impact seems limited in patients without distant 
metastatic disease.  
The results in this thesis seem to support the assumption that MMPs are of importance, 
especially in the early stage, of tumour invasion and progression. Results in paper I and IV 
suggested that MMPs are over-expressed in the invasive period of the tumour when lymph 
node metastasis occur. There are also indications of lower MMP expression in all tissue 
compartments (mucosa, tumour and plasma) in patients with distant metastatic disease, 
indicating that once dissemination has occurred, the local expression might no longer be of 
importance.  
 
Although it seems logical that MMPs are expressed locally during tumour invasion, the 
association of MMP-1 expression in adjacent tumour free mucosa with cancer specific 
survival was unexpected. This also means that prognostic information would be accessible 
in the preoperative setting through a mucosal biopsy. However, the biological background 
for the differential association of tissue remodelling factors with CSS in colon and rectal 
cancer is unclear and needs to be further understood.  
Lastly, the findings in this thesis suggest a different view on the role of apparently 
macroscopically normal mucosa in the tumour-bearing segment, as it seems evident that 
important changes in the microenvironment, even remote from the tumour, are present. 
 
Future perspectives 
Validation of MMP-1 expression in tumour free mucosa as a future prognostic marker in 
colon cancer would be valuable. Further evaluation of MMP-1 expression in mucosa in the 
adjacent tumour free bowel in relation to the increasing distance from the primary tumour 
could give important insight to the regulation of the tumour microenvironment in 
colorectal cancer. It is also conceivable that the prognostic strength for CSS is variable in 
relation to the distance from the tumour, and it would be important to evaluate if the 
prognostic information is reduced with increasing the distance from the tumour. This study 
design might give the opportunity to evaluate if changes in the microenvironment of the 
tumour are present regardless where the intestinal mucosal biopsy is taken.  
Further investigation of the matrix in the desmoplastic stroma and the invasive zone of the 
tumour seem warranted. Preferable techniques would be the use of micro-dissection, as 
this would facilitate the analysis of specific host matrix components. This could perhaps 
26
 27 
eliminate confounding regulatory factors generated by the tumour, and aid the specific 
evaluation of the microenvironment and extracellular matrix surrounding tumour tissue.   
One of the most important questions not answered by this thesis is if factors capable of 
matrix degradation, could aid in the identification of stage II patients with high risk of poor 
survival. These patients are problematic to study, as there are fewer deaths in this subgroup 
of patients, necessitating large cohorts. These studies would preferably be performed as 
prospectively controlled, multi-centre trials.  
The fundamental principle of the pre- and postoperative classification of a tumour is to 
optimise neo-adjuvant, adjuvant and surgical treatment. Our results indicate that a mucosal 
biopsy has a similar prognostic association with survival as N-status. However, N-status 
information cannot be obtained until the histopathology report is available after surgery. 
The information obtained in a mucosal biopsy could therefore provide the argument to 
offer neo-adjuvant therapy to high-risk patients and to optimise surgical technique in order 





Kolorektal cancer är den vanligaste formen av cancer i Sverige efter de könsbundna 
tumörformerna (prostata cancer för män och bröstcancer för kvinnor). Trots betydande 
medicinska och kirurgiska framsteg är dödligheten i kolorektal cancer mellan 40-50%. 
Prognosen är beroende av hur djupt tumören infiltrerar i tarmväggen, samt huruvida 
tumören utvecklat lymfkörtelspridning i tarmkäxet. Den grundläggande 
tumörklassifikationen som är baserad på patologens preparatundersökning är 
otillfredsställande och behovet av prognostiska faktorer som ytterligare skulle förbättra 
diagnostiken av patienter med risk för cancerspecifik död är stort. 
För att kunna tillväxa och sprida sig måste tumören bryta igenom anatomiska barriärer, 
såsom tarmens muskellager och underliggande stödjevävnad. Avhandlingens hypotes var 
att faktorer som deltar i denna nedbrytningsprocess såsom matrix metalloproteinaser 
(MMPs) och dess aktivatorer och inhibitorer (urokinase plasminogen activator, (uPA), 
plasminogen activating inhibitor-1 (PAI-1)), går att mäta i tumörvävnad, tumörfri vävnad 
samt i blod och att dessa faktorer skulle kunna relateras till tumörstadium och/eller kunna 
prognostisera cancerspecifik död. 
Patienter med kolorektal cancer inkluderades under tidsperioden 1999-2004. I samtliga 
fyra delarbeten togs vävnadsbiopsier från tumörvävnad, närliggande tumörfri slemhinna 
samt blod under det kirurgiska ingreppet. Proteinnivåer av vävnadsremodellerande 
proteaser analyserades. 
Vi fann signifikant högre koncentrationer av samtliga analyserade markörer i tumörvävnad 
jämfört med i tumörfri slemhinna. Detta indikerar en aktiv ombyggnad i tumören. Såväl 
reglerande plasminogen associerade faktorer som proteolytiska enzymer var associerade 
med den diagnostiserade postoperativa tumörklassifikationen.  
Våra resultat indikerar att faktorer som deltar i vävnads remodellering är associerade med 
cancerspecifik död, samt att denna association skiljer sig mellan koloncancer och 
rektalcancer. Ett oväntat fynd var att den tumörfria tarmslemhinnan avspeglade 
tumörprogression och att markörerna (MMP-1 i koloncancer och uPA i rektalcancer) här 
förefaller vara associerade med cancerspecifik överlevnad.  
Resultaten i denna avhandling talar för att man vid evalueringen av biomarkörer för 
kolorektal cancer bör ta hänsyn till tumörens lokalisation i grovtarmen. Resultaten 
indikerar även att information angående patientens prognos, som nu är beroende av 
patologutlåtandet efter det kirurgiska ingreppet, skulle kunna vara tillgängligt redan innan 
det kirurgiska ingreppet genom att analysera en provbit från den tumörnära, men 
makroskopiskt tumörfria tarmslemhinnan. Denna information skulle kunna identifiera 
patienter med ökad risk för cancerspecifik död, samt även ge förutsättningar för att innan 
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